{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:16:12Z","timestamp":1783476972900,"version":"3.55.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ijbiomac.2026.151384","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:47:21Z","timestamp":1773967641000},"page":"151384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["\u03b2-Arrestin and receptor tyrosine kinases in non-small cell lung cancer: A comprehensive review"],"prefix":"10.1016","volume":"356","author":[{"given":"Rima","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiman Chandra","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151384_bb0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-023-01436-2","article-title":"Emerging evidence and treatment paradigm of non-small cell lung cancer","volume":"16","author":"Liu","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.151384_bb0010","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non\u2013small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151384_bb0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non\u2013small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"7957","key":"10.1016\/j.ijbiomac.2026.151384_bb0020","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41586-023-05729-x","article-title":"The evolution of non-small cell lung cancer metastases in TRACERx","volume":"616","author":"Al Bakir","year":"2023","journal-title":"Nature"},{"issue":"7955","key":"10.1016\/j.ijbiomac.2026.151384_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","article-title":"Lung adenocarcinoma promotion by air pollutants","volume":"616","author":"Hill","year":"2023","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.ijbiomac.2026.151384_bb0030","doi-asserted-by":"crossref","first-page":"15284","DOI":"10.3390\/ijms242015284","article-title":"Novel mouse cell lines and in vivo models for human high-grade neuroendocrine lung carcinoma, small cell lung carcinoma (SCLC), and large cell neuroendocrine carcinoma (LCNEC)","volume":"24","author":"Recuero","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151384_bb0035","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3390\/life13061284","article-title":"Lung segmentectomy in NSCLC surgery","volume":"13","author":"Salvicchi","year":"2023","journal-title":"Life"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151384_bb0040","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.gendis.2022.07.023","article-title":"Non-small cell lung carcinoma (NSCLC): implications on molecular pathology and advances in early diagnostics and therapeutics","volume":"10","author":"Padinharayil","year":"2023","journal-title":"Genes Dis."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151384_bb0045","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cllc.2023.01.004","article-title":"Antibiotic treatment is an independent poor risk factor in NSCLC but not in melanoma patients who had received anti-PD-1\/L1 monotherapy","volume":"24","author":"Vihinen","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151384_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2023.100515","article-title":"Meta-analysis of rates and risk factors for local recurrence in surgically resected patients with NSCLC and differences between Asian and non-Asian populations","volume":"4","author":"Varlotto","year":"2023","journal-title":"JTO Clin. Res. Reports"},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.151384_bb0055","doi-asserted-by":"crossref","first-page":"13637","DOI":"10.1002\/cam4.5975","article-title":"Understanding the patient experience and treatment benefits in patients with non\u2013small-cell lung cancer with brain metastasis","volume":"12","author":"Cella","year":"2023","journal-title":"Cancer Med."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.151384_bb0060","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.molcel.2023.04.025","article-title":"Structural snapshots uncover a key phosphorylation motif in GPCRs driving \u03b2-arrestin activation","volume":"83","author":"Maharana","year":"2023","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151384_bb0065","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1124\/pharmrev.121.000302","article-title":"\u03b2\u2212Arrestins: structure, function, physiology, and pharmacological perspectives","volume":"75","author":"Wess","year":"2023","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151384_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2022.08.005","article-title":"Structural snapshot of a \u03b2-arrestin-biased receptor","volume":"44","author":"Sarma","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"issue":"797","key":"10.1016\/j.ijbiomac.2026.151384_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adf2173","article-title":"Unraveling allostery within the angiotensin II type 1 receptor for G\u03b1q and \u03b2-arrestin coupling","volume":"16","author":"Cao","year":"2023","journal-title":"Sci. Signal."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151384_bb0080","article-title":"Anti-proliferative effects of beta-blocker propranolol on human lung cancer and noncancer cells","volume":"124","author":"Terzi","year":"2023","journal-title":"Bratislava Med. J.\/BratislavskeLekarskeListy"},{"key":"10.1016\/j.ijbiomac.2026.151384_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110251","article-title":"Psychological distress influences lung cancer: advances and perspectives on the immune system and immunotherapy","volume":"121","author":"Gui","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151384_bb0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12943-023-01903-x","article-title":"Targeting CRAF kinase in anti-cancer therapy: progress and opportunities","volume":"22","author":"Wang","year":"2023","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.151384_bb0095","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/febs.16683","article-title":"11-Cl-BBQ, a select modulator of AhR-regulated transcription, suppresses lung cancer cell growth via activation of p53 and p27Kip1","volume":"290","author":"Nguyen","year":"2023","journal-title":"FEBS J."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151384_bb0100","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/kjm2.12752","article-title":"Neferine inhibits the development of lung cancer cells by downregulating TGF-\u03b2 to regulate MST1\/ROS-induced pyroptosis","volume":"39","author":"Zhong","year":"2023","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151384_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2023.14003","article-title":"RRM2-mediated Wnt\/\u03b2-catenin signaling pathway activation in lung adenocarcinoma: a potential prognostic biomarker","volume":"26","author":"Jiang","year":"2023","journal-title":"Oncol. Lett."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151384_bb0110","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.7150\/ijms.84566","article-title":"STARD12\/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis","volume":"20","author":"Zhang","year":"2023","journal-title":"Int. J. Med. Sci."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151384_bb0115","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.3390\/molecules28052231","article-title":"Bufalin-mediated regulation of cell signaling pathways in different cancers: spotlight on JAK\/STAT, Wnt\/\u03b2-catenin, mTOR, TRAIL\/TRAIL-R, and non-coding RNAs","volume":"28","author":"Farooqi","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151384_bb0120","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151384_bb0125","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.gastro.2023.01.041","article-title":"N6-methyladenosine\u2013mediated up-regulation of FZD10 regulates liver cancer stem cells\u2019 properties and lenvatinib resistance through WNT\/\u03b2-catenin and hippo signaling pathways","volume":"164","author":"Wang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijbiomac.2026.151384_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114491","article-title":"New insights about the PDGF\/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies","volume":"161","author":"Pandey","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.151384_bb0135","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1021\/acs.jafc.2c06775","article-title":"Ursolic acid suppresses colorectal cancer by down-regulation of Wnt\/\u03b2-catenin signaling pathway activity","volume":"71","author":"Zhao","year":"2023","journal-title":"J. Agric. Food Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151384_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113439","article-title":"Hypoxia induced \u03b2-catenin lactylation promotes the cell proliferation and stemness of colorectal cancer through the want signaling pathway","volume":"422","author":"Miao","year":"2023","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ijbiomac.2026.151384_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115015","article-title":"Evaluation of the association of chronic inflammation and cancer: insights and implications","volume":"164","author":"Nigam","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2026.151384_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216019","article-title":"Luteolin inhibits the TGF-\u03b2 signaling pathway to overcome bortezomib resistance in multiple myeloma","volume":"554","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.151384_bb0155","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.3390\/cancers15143542","article-title":"Application of radiomics in prognosing lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ijbiomac.2026.151384_bb0160","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.cllc.2024.01.005","article-title":"Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in metastatic non-small cell lung cancer patients with poor performance status and epidermal growth factor receptor mutations: findings from the Japanese lung cancer registry database","volume":"25","author":"Okuma","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ijbiomac.2026.151384_bb0165","first-page":"JCO","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor\u2013mutated metastatic non\u2013small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","author":"Mok","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.151384_bb0170","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non\u2013small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151384_bb0175","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S1470-2045(21)00401-0","article-title":"Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery","volume":"22","author":"Chang","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151384_bb0180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1470-2045(21)00606-9","article-title":"Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial","volume":"23","author":"Le Pechoux","year":"2022","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151384_bb0185","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvantnivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151384_bb0190","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non\u2013small-cell lung cancer: a phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.151384_bb0195","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/jamaoncol.2021.2301","article-title":"Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non\u2013small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial","volume":"7","author":"Jabbour","year":"2021","journal-title":"JAMA Oncol."},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.151384_bb0200","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non\u2013small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.151384_bb0205","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/cncr.33083","article-title":"A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non\u2013small cell lung cancer: Hoosier Cancer Research Network LUN 14-179","volume":"126","author":"Durm","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2026.151384_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-020-01648-1","article-title":"Circular RNA circ-CPA4\/let-7 miRNA\/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC)","volume":"39","author":"Hong","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151384_bb0215","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","volume":"7","author":"Akamatsu","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ijbiomac.2026.151384_bb0220","article-title":"Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in the Netherlands: a retrospective, nationwide registry study","volume":"27","author":"Gijtenbeek","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"issue":"15","key":"10.1016\/j.ijbiomac.2026.151384_bb0225","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41388-023-02645-2","article-title":"Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3\u03b2 Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer","volume":"42","author":"Huang","year":"2023","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/j.ijbiomac.2026.151384_bb0230","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.20.00297","article-title":"Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase II study","volume":"38","author":"Zhou","year":"2020","journal-title":"J. ClinOncol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.151384_bb0235","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial","volume":"40","author":"Le","year":"2022","journal-title":"J ClinOncol."},{"key":"10.1016\/j.ijbiomac.2026.151384_bb0240","article-title":"A phase II study of trastuzumabmonotherapy in pretreated patients with non-small cell lung cancers (NSCLCs) harboring HER2 alterations: HOT1303-B trial [abstract]","volume":"29(suppl 8):VIII540","author":"Kinoshita","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.151384_bb0245","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2022.05.009","article-title":"Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer","volume":"171","author":"van Berge Henegouwen","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.151384_bb0250","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.21.01455","article-title":"Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non\u2013 small-cell lung cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 trial","volume":"40","author":"Mazieres","year":"2022","journal-title":"J ClinOncol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151384_bb0255","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumabderuxtecan: a dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151384_bb0260","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumabderuxtecan in HER2-mutant non\u2013small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.ijbiomac.2026.151384_bb0265","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ijbiomac.2026.151384_bb0270","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.151384_bb0275","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose- finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J ClinOncol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151384_bb0280","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14\u2013mutated or MET-amplified on\u2013small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151384_bb0285","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non\u2013small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151384_bb0290","first-page":"1017","article-title":"Crizotinib in patients with MET-amplified NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J ThoracOncol."},{"issue":"16_suppl","key":"10.1016\/j.ijbiomac.2026.151384_bb0295","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9008","article-title":"9008 Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: updated results from the CHRYSALIS study","volume":"40","author":"Krebs","year":"2022","journal-title":"J ClinOncol."},{"issue":"35","key":"10.1016\/j.ijbiomac.2026.151384_bb0300","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-lung01, a phase II trial of patritumabderuxtecan (HER3-DXd) in epidermal growth factor receptor\u2013mutated non\u2013small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151384_bb0305","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.151384_bb0310","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1158\/1078-0432.CCR-21-3194","article-title":"A randomized phase II study comparing nivolumab with carboplatin\u2013pemetrexed for EGFR-mutated NSCLC with resistance to EGFR tyrosine kinase inhibitors (WJOG8515L)","volume":"28","author":"Hayashi","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151384_bb0315","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumabderuxtecan (HER3-DXd) in EGFR inhibitor\u2013resistant, EGFR-mutated non\u2013small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.151384_bb0320","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1078-0432.CCR-21-3359","article-title":"HER3 augmentation via blockade of EGFR\/AKT signaling enhances anticancer activity of HER3-targeting patritumabderuxtecan in EGFR-mutated non\u2013small cell lung cancer","volume":"28","author":"Yonesaka","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151384_bb0325","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151384_bb0330","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non\u2013small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.151384_bb0335","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamaoncol.2022.5959","article-title":"Atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non\u2013small cell lung cancer with high tumor mutation burden: a nonrandomized controlled trial","volume":"9","author":"Provencio","year":"2023","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151384_bb0340","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non\u2013small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.151384_bb0345","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41419-023-05945-3","article-title":"\u03b2-arrestin 2 negatively regulates lung cancer progression by inhibiting the TRAF6 signaling axis for NF-\u03baB activation and autophagy induced by TLR3 and TLR4","volume":"14","author":"Kim","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151384_bb0350","first-page":"1","article-title":"The EDN1\/EDNRA\/\u03b2-arrestin axis promotes colorectal cancer progression by regulating STAT3 phosphorylation","volume":"62","author":"Lee","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151384_bb0355","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/cells13060480","article-title":"Functional selectivity of cannabinoid type 1 G protein-coupled receptor agonists in transactivating glycosylated receptors on cancer cells to induce epithelial\u2013mesenchymal transition metastatic phenotype","volume":"13","author":"Bunsick","year":"2024","journal-title":"Cells"},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.151384_bb0360","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1002\/cncr.29640","article-title":"Stereotactic body radiation therapy versus no treatment for early stage non\u2013small cell lung cancer in medically inoperable elderly patients: a National Cancer Data Base analysis","volume":"121","author":"Nanda","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.151384_bb0365","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/s41419-022-05307-5","article-title":"PLEKHH2 binds \u03b2-arrestin1 through its FERM domain, activates FAK\/PI3K\/AKT phosphorylation, and promotes the malignant phenotype of non-small cell lung cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151384_bb0370","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41419-021-04485-y","article-title":"Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151384_bb0375","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.3892\/mmr.2020.11553","article-title":"miR-379-5p inhibits cell proliferation and promotes cell apoptosis in non-small cell lung cancer by targeting \u03b2-arrestin-1","volume":"22","author":"Jiang","year":"2020","journal-title":"Mol. Med. Rep."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.151384_bb0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304941","article-title":"Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: a systematic review and single-arm meta-analysis","volume":"19","author":"Cui","year":"2024","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.151384_bb0385","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non\u2013small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.151384_bb0390","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/oncolo\/oyae250","article-title":"Highlights of ASCO 2024","volume":"29","author":"Neugut","year":"2024","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.151384_bb0395","first-page":"0","article-title":"Melanoma survival strategies: the intrinsic apoptotic pathway\u2013upstream and downstream regulators","volume":"23","author":"de Freitas Sousa","year":"2017","journal-title":"J. Morphol. Sci."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026013103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026013103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:23:23Z","timestamp":1783473803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026013103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":79,"alternative-id":["S0141813026013103"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151384","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b2-Arrestin and receptor tyrosine kinases in non-small cell lung cancer: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.151384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"151384"}}